ibrance 帕博西尼

IBRANCE – A Revolutionary Drug in the Fight Against Breast Cancer Breast cancer is a serious health concern for women all around the world. According to statistics, breast cancer is the most common

作者头像.jpg
药直供药师
 

认证作者徽章

药直供执业药师
  • 帕博西尼

    帕博西尼

    印度卢修斯

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼

    帕博西尼

    孟加拉伊思达

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼

    帕博西尼

    孟加拉碧康制药

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼

    帕博西尼

    孟加拉耀品国际

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼 Palbociclib Parcini

    帕博西尼 Palbociclib Parcini

    老挝东盟制药

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

IBRANCE – A Revolutionary Drug in the Fight Against Breast Cancer

Breast cancer is a serious health concern for women all around the world. According to statistics, breast cancer is the most common cancer in women globally, with over 2 million new cases diagnosed every year. While there have been advances in treatment options, there is still a lot of work to be done to cure this disease. But the good news is that there could be a game-changer drug in the market – IBRANCE.

What is IBRANCE?

IBRANCE is a brand name for the drug palbociclib. Palbociclib is a type of targeted therapy that is used in combination with other drugs to treat advanced breast cancer in postmenopausal women. It works by blocking enzymes called cyclin-dependent kinase 4 and 6 (CDK4/6), which promote the growth of cancer cells. It has been shown to significantly slow down the progression of advanced breast cancer.

Why is it So Revolutionary?

IBRANCE is revolutionary because it is one of the few drugs approved by the FDA that specifically targets certain genetic mutations found in breast cancer. Additionally, it was the first CDK4/6 inhibitor to be approved by the FDA, making it a groundbreaking drug.

Clinical Trials

In clinical trials, palbociclib was used in combination with an aromatase inhibitor (a type of medication used to treat breast cancer) and was shown to be effective in slowing down the progression of cancer in women with advanced breast cancer. In one trial, the median progression-free survival (PFS) for patients who received palbociclib was 20.2 months, compared to 10.2 months for patients who received a placebo.

Side Effects

Like all drugs, palbociclib does have some side effects, although they are typically manageable. The most common side effects include:

- Fatigue

- Nausea

- Diarrhea

- Low white blood cell count (meaning an increased risk of infection)

Conclusion

IBRANCE is a remarkable drug that has shown positive results in the treatment of advanced breast cancer in postmenopausal women. It has been shown to be effective in slowing down the progression of cancer, and it is easy to manage its side effects. While there is still work to be done to completely cure breast cancer, IBRANCE is a significant step in the right direction, and it gives hope to patients and doctors alike.

注:本站所有内容仅供参考,不代表药直供立场(如有错漏,请帮忙指正),转载请注明出处。不作为诊断及治疗依据,不可替代专业医师诊断、不可替代医师处方。本站不承担由此导致的相关责任!

浏览量: 218
发布时间: 2023-03-29 18:57:15
  • 帕博西尼基本信息

    帕博西尼

    帕博西尼

    印度卢修斯

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼基本信息

    帕博西尼

    帕博西尼

    孟加拉伊思达

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼基本信息

    帕博西尼

    帕博西尼

    孟加拉碧康制药

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼基本信息

    帕博西尼

    帕博西尼

    孟加拉耀品国际

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

  • 帕博西尼 Palbociclib Parcini基本信息

    帕博西尼 Palbociclib Parcini

    帕博西尼 Palbociclib Parcini

    老挝东盟制药

    治疗晚期转移性乳腺癌,显著延长中位无进展生存期

乳腺癌推荐药品

相关问答
最新资讯
本网站不销售任何药品,只做药品信息资讯展示!
Copyright© 2022-2026 药直供 版权所有
互联网药品信息证书编号:粤网药信备字〔2026〕第00473号
网站转让:qq727472001

头部背景.jpg 寻找药品.jpg